Atomoxetine + placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

ADHD

Conditions

ADHD, Comorbid Alcohol Abuse

Trial Timeline

Aug 1, 2004 → Jan 1, 2006

NCT ID

NCT00190957

About Atomoxetine + placebo

Atomoxetine + placebo is a approved stage product being developed by Eli Lilly for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00190957. Target conditions include ADHD, Comorbid Alcohol Abuse.

What happened to similar drugs?

9 of 20 similar drugs in ADHD were approved

Approved (9) Terminated (3) Active (10)

✅atomoxetineEli LillyApproved

✅Strattera (atomoxetine)Eli LillyApproved

✅Atomoxetine Hydrochloride + placeboEli LillyApproved

✅atomoxetine (Strattera)Eli LillyApproved

🔄dasotraline + PlaceboSumitomo PharmaPhase 3

🔄dasotraline 4mgSumitomo PharmaPhase 3

🔄Focalin XRNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00962104	Phase 3	Completed	Aug 1, 2009	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00716274	Approved	Completed	Sep 1, 2008	Jul 1, 2016	Attention Deficit Hyperactivity Disorder
NCT00607919	Approved	Completed	Mar 1, 2008	Feb 1, 2011	Attention Deficit Hyperactivity Disorder
NCT00546910	Approved	Completed	Oct 1, 2007	May 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00617201	Phase 2	Completed	Jul 1, 2007	Aug 1, 2011	Substance Abuse
NCT00406354	Approved	Completed	Nov 1, 2006	Jan 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00380692	Approved	Completed	Oct 1, 2006	Oct 1, 2008	Autistic Disorder
NCT00260533	Phase 2/3	Completed	Nov 1, 2005	Jul 1, 2008	Generalized Social Phobia
NCT00191542	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191295	Phase 2/3	Completed	Feb 1, 2005	Sep 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00190957	Approved	Completed	Aug 1, 2004	Jan 1, 2006	ADHD
NCT00386581	Phase 3	Completed	Jul 1, 2004	Feb 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00611533	Pre-clinical	Completed	May 1, 2004	Apr 1, 2008	Menopause

Competing Products

20 competing products in ADHD

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Strattera (atomoxetine)	Eli Lilly	Approved	43
Atomoxetine Hydrochloride + placebo	Eli Lilly	Approved	43
atomoxetine (Strattera)	Eli Lilly	Approved	43
Atomoxetine + stimulants (any approved ADHD medication)	Eli Lilly	Pre-clinical	26
dasotraline + Placebo	Sumitomo Pharma	Phase 3	40
dasotraline	Sumitomo Pharma	Phase 1	29
dasotraline 4mg	Sumitomo Pharma	Phase 3	40
AZD1446 + AZD1446 + AZD1446 + Placebo	AstraZeneca	Phase 2	35
Placebo + AZD3480 + AZD3480	AstraZeneca	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Focalin XR	Novartis	Phase 3	40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
Dexmethylphenidate HCl extended-release capsules	Novartis	Phase 3	40
Methylphenidate hydrochloride	Novartis	Phase 3	40
Focalin XR	Novartis	Phase 3	40
methylphenidate HCl ERCT + Placebo	Pfizer	Approved	35
methylphenidate HCl ERCT	Pfizer	Approved	35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR	Pfizer	Approved	43
Brexpiprazole	Lundbeck	Phase 1	26